Obesity: Gut Hormone Receptors Retain Commercial Prominence

0
61

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Summary

Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market’s clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology.

Report Sample includes:

– Table of Contents

– List of Tables & Figures

– Charts

– Research Methodology

Get FREE Sample of this Report at https://www.24marketreports.com/report-sample/obesitygut-hormone-receptors-retain-commercial-prominence–910

The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline.

Scope

– The obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets. Which drug classes are used to treat this disease How do the drug classes in the market compare with those in the pipeline

– There are 267 pipeline programs in active development for obesity, respectively. What proportion of these products are first-in-class How does first-in-class innovation vary by indication, development stage and molecular target class

– Which molecular target classes are prominently represented in the first-in-class obesity pipeline Which first-in-class targets have been identified as most promising for obesity, and is there any overlap

– Which companies are the key players within the obesity market Who has been involved in the most licensing and co-development deals for obesity products Which first-in-class products have prior deal involvement

Reasons to buy

– Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems, epidemiology, and treatment options for obesity.

– Visualize the composition of the obesity markets in terms of dominant molecule types and molecular targets. This knowledge allows a competitive understanding of gaps in the current market.

– Analyze and compare the obesity pipeline and stratify by stage of development, molecule type, and molecular target.

– Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products for each indication have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.

– Recognize commercial opportunities by identifying first-in-class obesity pipeline products that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for obesity first-in-class products.

Get the Complete Report & TOC at https://www.24marketreports.com/life-sciences/obesitygut-hormone-receptors-retain-commercial-prominence–910

CONTACT US:

276 5th Avenue, New York , NY 10001,United States

International: (+1) 646 781 7170

Email: help@24marketreports.com

Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports

LEAVE A REPLY

Please enter your comment!
Please enter your name here